Preliminary Observations on the Use of Topical Tazarotene to Treat Basal-Cell Carcinoma
- 2 December 1999
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (23), 1767-1768
- https://doi.org/10.1056/nejm199912023412312
Abstract
Tazarotene is a novel receptor-selective retinoid originally developed for the topical treatment of mild-to-moderate plaque psoriasis.1 On the basis of recent hypotheses about the effects of this agent on the differentiation and proliferation of keratinocytes,2 we performed an open-label clinical trial to evaluate the efficacy and tolerability of topical tazarotene (0.1 percent in gel) in the treatment of basal-cell carcinoma.Keywords
This publication has 3 references indexed in Scilit:
- The pathogenesis of psoriasis and the mechanism of action of tazaroteneJournal of the American Academy of Dermatology, 1998
- Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effectJournal of the American Academy of Dermatology, 1997
- In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanomaJournal of the American Academy of Dermatology, 1987